OpenAI CEO Sam Altman has long been vocal about his belief that AI will transform humanity—but he’s also betting heavily on transforming human biology itself. In one of the boldest personal investments in longevity to date, Altman committed $180 million to Retro Biosciences, a stealth startup aiming to add 10 healthy years to human lifespan in the near term.

Retro’s approach is laser-focused:

• Cellular reprogramming without full pluripotency (avoiding cancer risks seen in earlier attempts).
• Autophagy enhancement — ramping up the body’s natural cellular cleanup processes.
• Mitochondrial optimization — targeting the energy powerhouses that degrade with age, driving fatigue and disease.

The goal isn’t vague “anti-aging”—it’s a concrete, measurable extension of healthspan, with the ambition to iterate toward much longer gains. Early preclinical work shows promise in extending lifespan in model organisms, and human trials are on the horizon.

Altman’s involvement is telling. The man steering the AI singularity sees biological longevity as equally critical—perhaps because superintelligent AI will need super-long-lived humans to guide (or coexist with) it.

This targeted strategy dovetails with the comprehensive, multi-modal rejuvenation in Suvudu’s Eternal Horizon Program™—where we combine reprogramming-inspired therapies, mitochondrial repair, senolytics, and tissue renewal to deliver verifiable age reversal and our guarantee of optimal health to age 150.

When the architect of ChatGPT invests nine figures in adding healthy decades, it’s not speculation—it’s strategy.

Sam Altman isn’t just building AI for the future—he’s building a body that can live to see it.

The elite are extending their timelines. How far will you extend yours?

Stay ahead with Star Path as we follow the leaders betting biggest on biology. Which AI leader’s longevity vision aligns with yours? Share below.